Vaccine preparation comprising a bacterial toxin adjuvant

US5182109A · kind A · utility

Assignees

• National Institutes of Health, Office of Technology Transfer · US
• The Kitasato Institute · JP

Inventors

• Shinichi Tamura · Tajimi, JP
• Takeshi Kurata · Tokyo, JP
• Chikara Aizawa · Saitama, JP
• Takashi Nagamine · Kawasaki, JP

Key dates

• Filing date: Apr 10, 1989
• Grant date: Jan 26, 1993
• Expiry date: Apr 10, 2009

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A vaccine preparation comprising in combination a vaccine and a toxin or subunit thereof as an effective component. The toxin is preferably a bacterial toxin, e.g. cholera toxin, staphylococcal .alpha.-hemolysin, staphylococcal .delta.-hemolysin, vibrio thermostable direct hemolysin, pertussis toxin or E. coli heat-labile toxin. The toxin can be a B subunit or a part of a B subunit of a toxin. The vaccine can be influenza vaccine, pertussis vaccine, Japanese encephalitis vaccine, mixed vaccine of pertussis, diphtheria and tetanus toxoid, hepatitis B vaccine, rota vaccine, measles vaccine, rubella vaccine, mumps vaccine, combined vaccine of measles, rubella and mumps, or mycoplasma vaccine. The ratio of vaccine to toxin or subunit thereof is 1:0.0001-1:10,000 (w/v). The vaccine can be intranasal vaccine, or can be in injectable form, spray form or oral administration form.